Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 1,452 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 1,452 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $26.80, for a total value of $38,913.60. Following the completion of the sale, the insider directly owned 123,452 shares in the company, valued at $3,308,513.60. This represents a 1.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gwenn Hansen also recently made the following trade(s):

• On Friday, October 30th, Gwenn Hansen sold 3,957 shares of Nurix Therapeutics stock. The shares were sold at an average price of $26.28, for a total value of $103,989.96.
• On Thursday, October 15th, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $36,300.00.
• On Tuesday, September 1st, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.47, for a total transaction of $36,982.44.
• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.36, for a total transaction of $100,143.96.

Nurix Therapeutics Trading Down 4.1%

Shares of NASDAQ NRIX traded down $1.10 during mid-day trading on Monday, hitting $25.70. The company had a trading volume of 2,348,532 shares, compared to its average volume of 2,495,734. The firm has a 50-day simple moving average of $24.98 and a two-hundred day simple moving average of $20.20. Nurix Therapeutics, Inc. has a one year low of $11.67 and a one year high of $28.23. The company has a market capitalization of $2.81 billion, a PE ratio of 11.13 and a beta of 1.82.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Monday, October 12th. The company reported $4.73 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The business had revenue of $673.06 million during the quarter, compared to the consensus estimate of $24.35 million. Sell-side analysts expect that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nurix Therapeutics

Several institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its position in Nurix Therapeutics by 95.4% during the third quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock valued at $30,000 after acquiring an additional 620 shares during the last quarter. Nykredit A S purchased a new stake in shares of Nurix Therapeutics in the 2nd quarter worth $32,000. Integrated Wealth Concepts LLC purchased a new position in Nurix Therapeutics during the 2nd quarter valued at about $33,000. Sterling Capital Management LLC raised its stake in Nurix Therapeutics by 310.4% in the third quarter. Sterling Capital Management LLC now owns 2,885 shares of the company’s stock worth $68,000 after buying an additional 2,182 shares in the last quarter. Finally, KBC Group NV purchased a new stake in shares of Nurix Therapeutics during the 1st quarter worth $34,000.

Wall Street Analyst Weigh In

Several research analysts recently commented on NRIX shares. UBS Group raised their price objective on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Morgan Stanley increased their price objective on Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Royal Bank Of Canada lowered their target price on Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating for the company in a research note on Tuesday, October 13th. Robert W. Baird boosted their price target on Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, October 13th. Finally, Truist Financial reduced their target price on Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, October 13th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.79.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.